Understanding payer perceptions of subjective endpoints
Analysis of the perception of subjective endpoints and caregiver perspective for communicating value for treatments in psychiatric indications
Scope:
EU4 + UK and Sweden
Therapy Area:
Psychiatry
Client:
Medium sized pharmaceutical company

VALUE DELIVERED
The client was provided with a comprehensive overview of the disease landscape, key unmet needs and the key drivers of payer and physician value for each indication: Schizophrenia, Alzheimer’s Disease, Autism Spectrum Disorder and Post-Traumatic Stress Disorder. Detailed analysis was performed on the perception and acceptance of behavioural/cognitive endpoints, patient quality of life, caregiver burden and quality of life, healthcare resource use and societal implications in HTA processes across markets
Strategic recommendations were generated on how the client can support the use of subjective endpoints and include the caregiver perspective across the entire clinical development programme; including recommendations on endpoint selection and validation, the positioning of endpoints in the clinical trial, and the inclusion of metrics of caregiver burden. The client was advised on the endorsement of endpoints outside of the pivotal trial to support the wider, holistic value narrative
Strategic recommendations were generated on how the client can support the use of subjective endpoints and include the caregiver perspective across the entire clinical development programme; including recommendations on endpoint selection and validation, the positioning of endpoints in the clinical trial, and the inclusion of metrics of caregiver burden. The client was advised on the endorsement of endpoints outside of the pivotal trial to support the wider, holistic value narrative